Despite the recent advances demonstrating the importance of the CD4+ T-cell response to tumor-specific mutations in the HLA-II context (51), we have not included HLA-II predictions in our models as they are much less reliable and have not begun full implementation in human trials as of yet (51, 52). Here, CD4 is linked to neoplasm.